OBJECTIVES: Rheumatoid arthritis (RA) is an autoimmune disease characterized by significant morbidity related to systemic and joint inflammation. With the availability of more targeted therapeutic approaches and the potential of disease remission, there is increased focus on utilizing patient reported outcomes to better evaluate RA treatment impact. Collecting such data efficiently, i.e., with relatively low cost and time expenditures, can be challenging. Our objective was to implement digital direct-to-patient methodology to collect and incorporate United States (US) RA patient data into the Outcome Measures in Rheumatoid Arthritis Clinical Trials (OMERACT) project to study the patient perspective on remission. METHODS: Leveraging a known community (MediGuard.org) of approximately 40,000 US RA patients with pre-existing consent to contact for research purposes, patients were contacted in December 2014 to obtain 50 responses to the OMERACT survey through a direct-to-patient digital communications platform.  Patients did not receive any honoraria for survey completion. RESULTS: The first survey was completed within seven minutes of initial digital outreach and the fiftieth within three hours. RA patients from 23 continental US states were represented.  Of the 50 patients, 82% were female, mean age 54.8 years; male patients were older, mean age 61.7 years.  RA diagnosis duration was 11.3 years average (range 1-40).  Comorbidities including other autoimmune and musculoskeletal conditions, diabetes, cardiovascular disease, malignancies were reported by 70%; 76% reported synthetic (72%) and/or targeted (44%) disease-modifying antirheumatic drug use; 84% reported current RA disease activity. Additional usable data were obtained including those on education, employment, health insurance, income, remission state, health assessment questionnaire, and patient global for the project. CONCLUSIONS: This analysis documents the feasibility of gaining rapid and relevant responses from a representative community RA patient population regarding their perspective on RA remission through our digital direct to patient portal.